Journal
CELL
Volume 181, Issue 7, Pages 1489-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.05.015
Keywords
-
Categories
Funding
- Departamento Administrativo de Ciencia, Tecnologia e Innovacion (COLCIENCIAS)
- Pontificia Universidad Javeriana
- NIH NIAID [AI42742]
- National Institutes of Health [75N9301900065, U19 AI118626]
- Bill and Melinda Gates Foundation
- LJI Institutional Funds
- Johnathan and Mary Tu Foundation
- NIAID [AI135078]
- UCSD Infectious Diseases Division [T32 AI007036, T32 AI007384]
Ask authors/readers for more resources
Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development, interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of pandemic control measures. Using HLA class I and II predicted peptide megapools, circulating SARS-CoV-2-specific CD8(+) and CD4(+) T cells were identified in similar to 70% and 100% of COVID-19 convalescent patients, respectively. CD4(+) T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the antiSARS-CoV-2 IgG and IgA titers. The M, spike, and N proteins each accounted for 11%-27% of the total CD4(+) response, with additional responses commonly targeting nsp3, nsp4, ORF3a, and ORF8, among others. For CD8(+) T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted. Importantly, we detected SARS-CoV-2-reactive CD4(+) T cells in similar to 40%-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating common cold coronaviruses and SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available